141 related articles for article (PubMed ID: 33868478)
1. DEK is highly expressed in breast cancer and is associated with malignant phenotype and progression.
Yang MQ; Bai LL; Wang Z; Lei L; Zheng YW; Li ZH; Huang WJ; Liu CC; Xu HT
Oncol Lett; 2021 Jun; 21(6):440. PubMed ID: 33868478
[TBL] [Abstract][Full Text] [Related]
2. DEK promotes the proliferation and invasion of lung cancers and indicates poor prognosis in lung adenocarcinomas.
Yang MQ; Bai LL; Lei L; Zheng YW; Wang Z; Li ZH; Liu CC; Huang WJ; Xu HT
Oncol Rep; 2020 Apr; 43(4):1338-1348. PubMed ID: 32020224
[TBL] [Abstract][Full Text] [Related]
3. The human DEK oncogene stimulates β-catenin signaling, invasion and mammosphere formation in breast cancer.
Privette Vinnedge LM; McClaine R; Wagh PK; Wikenheiser-Brokamp KA; Waltz SE; Wells SI
Oncogene; 2011 Jun; 30(24):2741-52. PubMed ID: 21317931
[TBL] [Abstract][Full Text] [Related]
4. DEK overexpression is correlated with the clinical features of breast cancer.
Liu S; Wang X; Sun F; Kong J; Li Z; Lin Z
Pathol Int; 2012 Mar; 62(3):176-81. PubMed ID: 22360505
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of DEK is an indicator of poor prognosis in patients with gastric adenocarcinoma.
Ou Y; Xia R; Kong F; Zhang X; Yu S; Jiang L; Zheng L; Lin L
Oncol Lett; 2016 Mar; 11(3):1823-1828. PubMed ID: 26998084
[TBL] [Abstract][Full Text] [Related]
6. DEK promoted EMT and angiogenesis through regulating PI3K/AKT/mTOR pathway in triple-negative breast cancer.
Yang Y; Gao M; Lin Z; Chen L; Jin Y; Zhu G; Wang Y; Jin T
Oncotarget; 2017 Nov; 8(58):98708-98722. PubMed ID: 29228721
[TBL] [Abstract][Full Text] [Related]
7. DEK: A novel early screening and prognostic marker for breast cancer.
Ying G; Wu Y
Mol Med Rep; 2015 Nov; 12(5):7491-5. PubMed ID: 26459608
[TBL] [Abstract][Full Text] [Related]
8. Gigantol inhibits cell proliferation and induces apoptosis by regulating DEK in non-small cell lung cancer.
Cai Y; Hao Y; Xu H; Chen K; Ren B
Exp Ther Med; 2021 Nov; 22(5):1317. PubMed ID: 34630671
[TBL] [Abstract][Full Text] [Related]
9. DEK protein overexpression predicts poor prognosis in pancreatic ductal adenocarcinoma.
Sun J; Bi F; Yang Y; Zhang Y; Jin A; Li J; Lin Z
Oncol Rep; 2017 Feb; 37(2):857-864. PubMed ID: 27959420
[TBL] [Abstract][Full Text] [Related]
10. Oncogene DEK is highly expressed in lung cancerous tissues and positively regulates cell proliferation as well as invasion.
Zhou QC; Deng XF; Yang J; Jiang H; Qiao MX; Liu HH; Qian Z; Hou LL; Hu HG
Oncol Lett; 2018 Jun; 15(6):8573-8581. PubMed ID: 29844811
[TBL] [Abstract][Full Text] [Related]
11. Silencing DEK downregulates cervical cancer tumorigenesis and metastasis via the DEK/p-Ser9-GSK-3β/p-Tyr216-GSK-3β/β-catenin axis.
Xu X; Zou L; Yao Q; Zhang Y; Gan L; Tang L
Oncol Rep; 2017 Aug; 38(2):1035-1042. PubMed ID: 28627610
[TBL] [Abstract][Full Text] [Related]
12. Expression of DEK in pancreatic cancer and its correlation with clinicopathological features and prognosis.
Zhao T; Qiu B; Zhou S; Ding G; Cao L; Wu Z
J Cancer; 2019; 10(4):911-917. PubMed ID: 30854097
[No Abstract] [Full Text] [Related]
13. Reduced expression of odd-skipped related transcription factor 1 promotes proliferation and invasion of breast cancer cells and indicates poor patient prognosis.
Wang Y; Lei L; Xu F; Xu HT
Oncol Lett; 2020 Sep; 20(3):2946-2954. PubMed ID: 32782611
[TBL] [Abstract][Full Text] [Related]
14. GTSE1 is involved in breast cancer progression in p53 mutation-dependent manner.
Lin F; Xie YJ; Zhang XK; Huang TJ; Xu HF; Mei Y; Liang H; Hu H; Lin ST; Luo FF; Lang YH; Peng LX; Qian CN; Huang BJ
J Exp Clin Cancer Res; 2019 Apr; 38(1):152. PubMed ID: 30961661
[TBL] [Abstract][Full Text] [Related]
15. The DEK oncogene activates VEGF expression and promotes tumor angiogenesis and growth in HIF-1α-dependent and -independent manners.
Zhang Y; Liu J; Wang S; Luo X; Li Y; Lv Z; Zhu J; Lin J; Ding L; Ye Q
Oncotarget; 2016 Apr; 7(17):23740-56. PubMed ID: 26988756
[TBL] [Abstract][Full Text] [Related]
16. NEDD4 expression is associated with breast cancer progression and is predictive of a poor prognosis.
Wan L; Liu T; Hong Z; Pan Y; Sizemore ST; Zhang J; Ma Z
Breast Cancer Res; 2019 Dec; 21(1):148. PubMed ID: 31856858
[TBL] [Abstract][Full Text] [Related]
17. DEK is a potential marker for aggressive phenotype and irinotecan-based therapy response in metastatic colorectal cancer.
Martinez-Useros J; Rodriguez-Remirez M; Borrero-Palacios A; Moreno I; Cebrian A; Gomez del Pulgar T; del Puerto-Nevado L; Vega-Bravo R; Puime-Otin A; Perez N; Zazo S; Senin C; Fernandez-Aceñero MJ; Soengas MS; Rojo F; Garcia-Foncillas J
BMC Cancer; 2014 Dec; 14():965. PubMed ID: 25515240
[TBL] [Abstract][Full Text] [Related]
18. The human DEK proto-oncogene is a senescence inhibitor and an upregulated target of high-risk human papillomavirus E7.
Wise-Draper TM; Allen HV; Thobe MN; Jones EE; Habash KB; Münger K; Wells SI
J Virol; 2005 Nov; 79(22):14309-17. PubMed ID: 16254365
[TBL] [Abstract][Full Text] [Related]
19. DEK Is a Potential Biomarker Associated with Malignant Phenotype in Gastric Cancer Tissues and Plasma.
Lee KF; Tsai MM; Tsai CY; Huang CG; Ou YH; Hsieh CC; Hsieh HL; Wang CS; Lin KH
Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31766266
[TBL] [Abstract][Full Text] [Related]
20. High expression of DEK is associated with poor prognosis in hepatocellular carcinoma.
Lee SY; Jung W; Lee J; Kim A; Kim HK; Kim BH
Histol Histopathol; 2019 Nov; 34(11):1279-1288. PubMed ID: 31066459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
